This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Conflict of Interest  • Medical Ethics  • Alert me on articles by topic  Social Bookmarking   What's this?

Eric J. Topol, MD; David Blumenthal, MD, MPP

JAMA. 2005;293:2654-2657.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Until recently, it was quite uncommon for physicians to have a consulting relationship with the investment community. But the relationship of physicians with financial entities has been radically transformed, with almost 1 of 10 US physicians currently engaged in a formal consultancy with the investment industry.^1-4 Because of investment firms’ interest in ongoing clinical research, the proportion of academic physicians who have relationships with these financial entities appears to be considerably higher. These relationships create opportunities both for useful exchange of information and for potential conflict of interest, particularly in the area of clinical research. In this article, we discuss the scope of the convergence between physicians and investment firms, the issues of conflict of interest, and propose recommendations for institutions and individuals.

Profile of Investment Firms

Several types of financial entities contact physicians for advice. These include individual stockbrokers and analysts, investment bankers, venture capital . . . [Full Text of this Article]

Author Affiliations: Office of the Provost, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, and Cleveland Clinic Foundation, Cleveland, Ohio (Dr Topol); Institute for Health Policy, Massachusetts General Hospital—Partners Health Care System, Harvard Medical School, Boston, Mass (Dr Blumenthal).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Physicians Advising Investment Firms
Michael A. Patmas
JAMA. 2005;294(15):1897.
EXTRACT | FULL TEXT  

Physicians Advising Investment Firms
Lindsay A. Hampson and Ezekiel J. Emanuel
JAMA. 2005;294(15):1897.
EXTRACT | FULL TEXT  

Physicians Advising Investment Firms—Reply
Eric J. Topol and David Blumenthal
JAMA. 2005;294(15):1897-1898.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Investment analysts and the American Society of Hematology
Steensma
Blood 2008;112:29-33.
ABSTRACT | FULL TEXT  

Secrecy and Integrity in Clinical Trials
Wells
JCO 2008;26:680-682.
FULL TEXT  

Ethics in Oncology: Consulting for the Investment Industry
Berlin et al.
JCO 2007;25:444-446.
ABSTRACT | FULL TEXT  

Interactions With the Investment Industry: Practical and Ethical Implications
The American Society of Clinical Oncology
JCO 2007;25:338-340.
FULL TEXT  

Physicians Advising Investment Firms
Patmas
JAMA 2005;294:1897-1897.
FULL TEXT  

Physicians Advising Investment Firms
Hampson and Emanuel
JAMA 2005;294:1897-1897.
FULL TEXT  

Wall Street and Clinical Trials
Steinbrook
NEJM 2005;353:1091-1093.
FULL TEXT